- Home
- »
- Clinical Diagnostics
- »
-
Laboratory Developed Tests Market Size Report, 2026-2033GVR Report cover
![Laboratory Developed Tests Market (2026 - 2033)Report]()
Laboratory Developed Tests Market (2026 - 2033)
Size, Share & Trends Analysis Report By Technology (Immunoassay, Molecular Diagnostics, Microbiology, Clinical Chemistry), By Application (Oncology, Nutritional & Metabolic Disease), By Region, And Segment Forecasts
Market Size, 2025
$14.1BMarket Estimate, 2026
$15.1BMarket Forecast, 2033
$24.6BCAGR, 2026–2033
7.3%Laboratory Developed Tests Market Summary
The global laboratory developed tests market size was valued at USD 14.1 billion in 2025 and is projected to grow from USD 15.1 billion in 2026 to USD 24.6 billion by 2033, at a CAGR of 7.3% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.5% in 2025. The market growth is attributed to the rising prevalence of cancer and genetic disorders, aided by the rising number of product launches.
Key Market Trends & Insights
- By technology: Molecular diagnostics segment led the market with the largest revenue share of 25.8% in 2025.
- By application: Oncology segment led the market with the largest revenue share of 22.0% in 2025.
Regional Highlights
- Largest regional market: North America (37.5% revenue share, 2025)
- By country: The U.S. held the largest market share in 2025.
Market Size & Forecast
- Market size in 2025: USD 14.1 Billion
- Estimated market size in 2026: USD 15.1 Billion
- Projected market size by 2033: USD 24.6 Billion
- CAGR (2026-2033): 7.3%
As per the National Cancer Institute, incidence of cancer is expected to increase to 23.6 million by 2030. Laboratory developed test (LDT) regulations are important for advancements in precision oncology because various tests are used for selection of therapy and to determine risk. Moreover, the increase in adoption of personalized medicines is further anticipated to fuel market growth.Genetic testing has been made widely available for direct consumer purchase for complex and common diseases. It is usually available through online channels, without the involvement of a healthcare professional. In 2017, FDA authorized the first DTC genetic test developed by 23andMe-PGS Genetic Health Risk test. This test would provide information about the risk of developing genetic diseases.
LDTs are important tools to rapidly incorporate new information and decide which drug to utilize for personalized therapy. They enable treatments to shift from a “one drug fits all” approach to a much more personalized approach based on the unique genetics of each person and their disease. Tests developed in the laboratory are critical in public health defense by allowing the identification of Severe Acute Respiratory Syndrome (SARS) or avian flu. Individualized laboratories perform and develop these tests, offering reliable and early diagnosis for several rare and complex diseases.
Furthermore, a significant number of product launches by key players have contributed to the market growth. Several LDTs, such as Invitae's Personalized Cancer Monitoring (PCM) test, which is accessible since June 2022 under an early-access program, have been made available in 2022. Although PCM is useful for tracking the development of lung cancer, the company plans to broaden its use as a pan-cancer monitoring test. Furthermore, in September 2021, Journey Biosciences announced the launch of NaviDKD diagnostic screening technology, which would help manage and prevent the risk of kidney complications related to diabetes.
Market Dynamics
The laboratory developed tests market is influenced by the growing demand for specialized diagnostic solutions that address unmet clinical needs where commercially available tests may not provide adequate coverage. Healthcare providers and reference laboratories increasingly utilize LDTs for complex disease diagnosis, precision medicine applications, rare genetic disorders, and emerging infectious diseases due to their ability to offer customized and clinically relevant testing. The market is also shaped by advances in molecular diagnostics, next generation sequencing, and biomarker discovery, which continue to expand the scope of laboratory innovation. A notable example of this trend can be observed through recent regulatory developments. For instance, in April 2024, the U.S. Food and Drug Administration finalized a rule outlining a phased oversight framework for laboratory developed tests, reflecting the growing importance of ensuring quality and consistency while maintaining access to innovative diagnostics. As healthcare systems continue to prioritize personalized care and earlier disease detection, laboratories are expected to invest in advanced testing capabilities, supporting sustained demand for LDTs across multiple therapeutic areas and clinical settings.
The increasing adoption of precision medicine is a key factor driving the laboratory developed tests market. Healthcare providers are seeking diagnostic solutions capable of identifying disease specific biomarkers, genetic mutations, and patient specific treatment pathways that are often not addressed by standardized commercial assays. LDTs enable laboratories to rapidly develop and validate tests for complex clinical conditions including oncology, rare genetic disorders, transplant monitoring, and infectious diseases. The growing use of advanced technologies such as next generation sequencing and molecular diagnostics has further strengthened the role of LDTs in supporting personalized healthcare strategies. An example of this trend can be seen in the continued expansion of precision oncology testing across clinical laboratories. For instance, in January 2025, Quest Diagnostics announced the availability of an enhanced cancer risk assessment offering that integrates genetic insights to support individualized patient management. As healthcare systems increasingly emphasize targeted treatment decisions and early disease detection, demand for specialized laboratory developed testing solutions is expected to remain strong.
The laboratory developed tests market faces challenges stemming from evolving regulatory requirements and increasing scrutiny of test validation, quality management, and clinical performance standards. As LDTs become more widely used in critical healthcare decisions, laboratories are required to invest additional resources in documentation, validation studies, quality systems, and regulatory compliance processes. These requirements can increase operational costs and extend the time needed to introduce new assays, particularly for smaller laboratories and academic medical centers that often drive diagnostic innovation. The resulting uncertainty surrounding future regulatory expectations may also influence investment decisions and limit the pace of new test development. A recent example highlights these concerns. For instance, in August 2024, the Association for Molecular Pathology filed a lawsuit challenging the U.S. Food and Drug Administration's laboratory developed test rule, arguing that the framework could impose substantial compliance costs on laboratories and potentially discourage innovation in specialized diagnostic testing. Such developments illustrate the regulatory complexities that continue to shape the market environment for laboratory developed tests.
The expanding use of genomic medicine presents a significant opportunity for the laboratory developed tests market. Advances in sequencing technologies, declining genomic testing costs, and increasing awareness of hereditary diseases are encouraging healthcare providers to adopt more comprehensive diagnostic approaches. Many rare diseases and complex genetic conditions lack widely available commercial diagnostic solutions, creating opportunities for laboratories to develop specialized tests tailored to specific patient populations. Furthermore, growing integration of genomic information into clinical practice is supporting demand for customized testing services in oncology, reproductive health, neurology, and pediatric medicine. The ability of laboratories to rapidly introduce innovative assays in response to emerging clinical needs provides an important competitive advantage within this segment. The market opportunity is reflected in ongoing investments across the genomic diagnostics landscape. For instance, in March 2025, Tempus AI expanded its precision medicine capabilities through strategic initiatives focused on genomic data utilization and clinical decision support. Such developments are expected to support broader adoption of advanced laboratory developed testing solutions in the coming years.
Market Concentration & Characteristics
Market growth stage is high, and pace of the growth is accelerating. The market is characterized by a high degree of innovation owing to the rising adoption of personalized medicine. LDTs are developed in-house out of necessity. Previously, lab-developed tests could be rapidly launched and developed as deployment does not require prior authorization or approval by a government agency. This makes LDTs efficient and responsive in situations where rapid adoption is required to adapt to changing circumstances or when the biomarkers that need to be measured have not yet been identified or standardized.
The market is also characterized by a high level of partnership and collaboration activity by the leading players. It is one of the most adopted strategies by players to enhance early commercialization of their products and improve the availability of products.
In November 2021, Human Health Services announced the withdrawal of an administration policy that directed the FDA to not include LDTs for premarket review, a category most adopted during the pandemic. According to the new legislation, the LDTs would require traditional marketing or emergency use authorization before commercialization. The shift in regulatory standards is expected to increase the reliability & accuracy of COVID-19 tests and enhance access to at-home diagnostics
LDT products with molecular diagnostic capabilities deliver effective results. Moreover, these tests allow early detection of diseases, maintaining a low threat of substitutes, whereas high prices of these tests are anticipated to encourage patients to shift to externally available substitutes. In addition, for detection of newer infections like SARS-CoV-2, the rate of internal substitution is high, which fuels the competitive rivalry, resulting in a moderate threat of substitutes.
End-user concentration is a significant factor in the global market. Diagnostics laboratories are preferred for care due to availability of various services under one roof. Molecular laboratories are dependent on robust molecular diagnostic techniques to integrate RNA/DNA sequences for detection of sequence variants linked with a particular prognosis, diagnosis, or therapeutic response. These tests are widely accepted by laboratories to keep abreast with new molecular discoveries and bring new discoveries to clinical practice.
Analyst Perspective
The Laboratory Developed Tests (LDTs) market is positioned for sustained growth, driven by increasing demand for precision medicine, personalized healthcare, and advanced molecular diagnostics. The growing prevalence of cancer, genetic disorders, infectious diseases, and rare conditions is encouraging healthcare providers to adopt highly specialized testing solutions that can address unmet clinical needs. LDTs offer laboratories the flexibility to develop customized assays for specific patient populations and emerging disease applications, making them an essential component of modern diagnostics.
Technological advancements in next-generation sequencing (NGS), polymerase chain reaction (PCR), digital pathology, bioinformatics, and multiomics are further expanding the capabilities and clinical utility of LDTs. These innovations are enabling earlier disease detection, improved treatment selection, and more accurate monitoring of disease progression. In particular, oncology and genetic testing applications are expected to remain key growth areas as precision medicine becomes increasingly integrated into routine clinical practice.
Despite strong growth prospects, evolving regulatory oversight and reimbursement uncertainties remain important challenges for market participants. Laboratories must continuously invest in clinical validation, quality management, and compliance processes to maintain competitiveness. However, established laboratory networks and innovative specialty testing providers are expected to benefit from growing demand for high-value diagnostic solutions. Overall, the market is anticipated to witness steady expansion as healthcare systems increasingly prioritize personalized diagnostics, preventive healthcare, and data-driven clinical decision-making.
Technology Insights
Based on technology, the molecular diagnostics segment led the market with the largest revenue share of 25.8% in 2025. attributed to the high adoption of molecular diagnostics tests for detection of all major parasitic, bacterial, and viral infections. Drawbacks of traditional molecular testing, such as complexity in growing organisms in manually equipped culture media, long turnaround time, absence of sensitivity, and poor in vitro kinetics have been addressed in advanced technologies, such as in situ hybridization and PCR. Some of the key pathogens usually diagnosed using multiplex PCR are Leishmania spp (leishmaniasis); C. parvum (diarrheal diseases); HSV-2 (meningitis & encephalitis); and HIV-1 & H. influenza.
The immunoassays segment is anticipated to grow at the fastest CAGR over the forecast period. The growth of the segment is attributed to the rising applications associated with immunoassays. Key applications of immunology are detection of infectious microbes, such as fungi, bacteria, and viruses, by detecting presence of their toxins.Moreover, key players are focusing on R&D about development of new immunological diagnostic instruments for assessment of individuals suspected of immune deficiency. For instance, in January 2023, Quanterix expanded its laboratory developed test portfolio with introduction of neurofilament light chain tests. This novel blood test increases crucial brain health biomarkers that help provide optimum clinical care and advance research.
Application Insights
Based on application, the oncology segment led the market with the largest revenue share of 22.0% in 2025. This is attributable to the increasing prevalence of cancer which further propels the demand for IVD.According to WCRF International, in 2020, there were an estimated 18.1 million new cases globally, out of which, 8.8 million were women and 9.3 million were men. Cancer is estimated to be the second most common cause of death in the U.S. Genomic and genetic variation molecular tests have become a crucial part of managing breast cancer. These tests can help predict breast cancer in patients with a family history of the condition. Moreover, growing awareness about the need for early diagnosis is expected to impel demand for oncology related LDTs.
The nutritional and metabolic disease segment is projected to witness at the fastest CAGR over the forecast period. Modern metabolomics is primarily defined by the use of mass spectrometry-based techniques in conjunction with bioinformatics data processing, which enables quick and complex study of metabolites with a high diagnostic accuracy of 90%-95%. Metabolomics fingerprinting and metabolomics profiling are the two most popular techniques used for studying metabolites.FDA and clinically approved complex metabolic diagnostic tests are not yet available. Only two relevant publications were found when searching for “metabolomics and laboratory test” in PubMed on March 25, 2021, which is a requirement for the development of the first comprehensive metabolomics test intended to identify Parkinson's disease in its early stages.
Regional Insights
North America laboratory developed tests industry accounted for the largest revenue share of 37.5% in 2025. This high share is owing to increasing healthcare expenditure, prevalence of chronic diseases, geriatric population, and government funding. Moreover, the outbreak of coronavirus positively impacted growth. The number of tests increased due to the outbreak of COVID-19 in response to increased demand for quick on-site screening.Furthermore, with the increasing prevalence of cancer and the rapid development of diagnosis, the market is undergoing significant growth. For instance, in June 2022, Neogenomics announced data on its LDT RaDaR assay for the detection of minimal residual disease (MRD) by its subsidiary Inivata Ltd.
U.S. Laboratory Developed Tests Market Trends
The laboratory developed tests market in the U.S. held the largest share in the North America region in 2025. Several key market players operating in the LDT market are introducing new products and entering into several strategic alliances, which is contributing to the country’s market growth.
Europe Laboratory Developed Tests Market Trends
The laboratory developed tests market in Europe was identified as a lucrative region in this industry. Several initiatives are taken by various companies in Europe to develop and commercialize LDTs. These initiatives demonstrate the growing importance of LDTs in the European diagnostic market and the significant investment being made by companies to develop & commercialize new diagnostic solutions.
The UK laboratory developed tests market is expected to grow at the fastest CAGR over the forecast period, due to presence of several key companies in the diagnostic industry, including Roche, Illumina, and Thermo Fisher Scientific, as well as smaller companies that focus on niche areas of diagnostics.
The laboratory developed tests market in France is expected to grow at the fastest CAGR over the forecast period. There have been several advancements in the field of LDTs in France. The healthcare system emphasizes the use of innovative technologies to improve patient outcomes, which has boosted the demand for LDTs in the country.
The Germany laboratory developed tests market is expected to grow at the fastest CAGR over the forecast period, due to strong presence of several companies in Germany, such as Roche Diagnostics, QIAGEN, bioMérieux, Siemens Healthineers, and Agilent Technologies, is involved in the development of LDTs, which focus on the development of innovative solutions for the healthcare industry.
Asia Pacific Laboratory Developed Tests Market Trends
The laboratory developed tests market in Asia Pacific growth is attributed to the rising initiatives being taken in the region to develop & commercialize LDTs which includes collaboration among academic institutions and research centers to develop new LDTs and validate their performance. This allows them to access the latest research and scientific knowledge, as well as benefit from the expertise of academic researchers. There is growing importance of LDTs in the European diagnostic market and the significant investment being made by companies to develop & commercialize new diagnostic solutions which fuel the market growth in the region.
The China laboratory developed tests market is expected to grow at the fastest CAGR over the forecast period. This is due to various initiatives undertaken by government, such as free cervical cancer screening campaigns for women of all ages and collaborations with nonprofit organizations to improve the accessibility of the tests.
The laboratory developed tests market in Japan is expected to grow at the fastest CAGR over the forecast period, owing to high government investment to reduce cancer prevalence. Many initiatives, such as government grants to various research institutes and companies, can help develop practical solutions to battle cancer.
Latin America Laboratory Developed Tests Market Trends
The laboratory developed tests market in Latin America was identified as a lucrative region in this industry. Increasing government expenditure on R&D, presence of skilled healthcare professionals, rising focus of multinational pharmaceutical companies in the clinical diagnostics sector, and increase in patient awareness levels are expected to drive market growth over the forecast period.
The Brazil laboratory developed tests market is expected to grow at the fastest CAGR over the forecast period, due to the rising prevalence of chronic diseases in the country due to the moderate standards of living, further increasing the need for advanced diagnostic and treatment options.
MEA Laboratory Developed Tests Market Trends
The laboratory developed tests market in MEA was identified as a lucrative region in this industry. The increasing prevalence of chronic diseases created a significant need for enhanced diagnostic tools and therapeutic alternatives in the country.
The Saudi Arabia laboratory developed tests market is expected to grow at the fastest CAGR over the forecast period, owing to the rapid launch of new products in the region and increasing number of government initiatives.
Key Laboratory Developed Tests Company Insights
Some of the key players operating in the global market include Illumina, Inc., QIAGEN, F. Hoffmann-La Roche Ltd., and Guardant Health.These players are involved in the development of novel NGS platforms and services that offer portability as well as efficiency of sequencing. Ambry Genetics,Epic Sciences, HelixDiagnostics are some of the emerging market participants in the global market. These companies are focusing on continually expanding the understanding of biology and human genome behind genetic diseases to develop novel platforms.
Key Laboratory Developed Tests Companies:
The following are the leading companies in the laboratory developed tests market.
- 23andMe, Inc.
- Abbott
- Guardant Health
- NeoGenomics Laboratories.
- Siemens Healthineers AG
- QIAGEN
- Illumina, Inc.
- F. Hoffmann-La Roche Ltd.
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Well-Established Players (Quest Diagnostics, Labcorp, Mayo Clinic Laboratories, ARUP Laboratories, Sonic Healthcare, NeoGenomics Laboratories)
- Focus on expanding specialized LDT portfolios across oncology, genetic testing, infectious diseases, immunology, and precision medicine. Emphasize laboratory network expansion, automation, advanced molecular diagnostics, strategic partnerships with healthcare providers, and investments in next-generation sequencing (NGS), digital pathology, and bioinformatics capabilities.
- Extensive laboratory infrastructure, broad test menus, strong reimbursement relationships, established physician networks, significant clinical expertise, and nationwide or global service reach. Strong regulatory compliance capabilities and access to large patient datasets support continuous test development and validation.
- High operational and compliance costs, dependence on reimbursement policies, increasing regulatory scrutiny of LDTs, and lengthy validation requirements. Large organizational structures may limit agility in rapidly adopting emerging technologies compared to smaller innovators.
Emerging & Regional Players (Fulgent Genetics, Invitae, Natera, Personalis, Ambry Genetics, regional specialty laboratories)
- Focus on niche disease areas, precision medicine applications, innovative biomarker discovery, genomic testing, and cost-effective specialty diagnostics. Emphasize partnerships with hospitals, academic institutions, and biotechnology companies to expand testing capabilities and strengthen clinical validation.
- Greater flexibility in innovation, specialized expertise in targeted disease segments, competitive pricing strategies, and faster development cycles. Ability to address underserved clinical needs through differentiated testing solutions and personalized diagnostic approaches.
- Limited testing capacity, smaller commercial footprint, lower brand recognition, and restricted access to large healthcare networks. Dependence on external funding, reimbursement expansion, and clinical adoption may constrain scalability and long-term market penetration.
Recent Developments
-
In January 2023, QIAGEN entered into a partnership with Helix to advance NGS companion diagnostics in hereditary disorders. The partnership would apply QIAGEN's global regulatory experience, NGS capabilities, and relationships with biopharma companies to power the Helix Laboratory Platform
-
In January 2023, Quanterix expanded its LDT portfolio with introduction of neurofilament light chain tests. This novel blood test increases crucial brain health biomarkers that help provide optimum clinical care and advance research
-
In January 2023, QIAGEN introduced the EZ2 Connect MDx platform for automated sample processing in diagnostic labs. This initiative was expected to help clinical labs perform consistent and effective nucleic acid purification
Laboratory Developed Tests Market Report Scope
Report Attribute
Details
Market size in 2025
USD 14.1 billion
Estimated market size in 2026
USD 15.1 billion
Projected market size by 2033
USD 24.6 billion
Growth rate
CAGR of 7.3% from 2026 to 2033
Historical data
2021 - 2024
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million/billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Application, Technology, Regional
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; and Kuwait
Key companies profiled
Quest Diagnostics Incorporated.; 23andMe, Inc.; Abbott; Guardant Health; NeoGenomics Laboratories.; Siemens Healthineers AG; QIAGEN; Illumina; Inc. F. Hoffmann-La Roche Ltd.
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Laboratory Developed Tests Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global laboratory developed tests market report based on technology, application, and region:
-
Technology Outlook (Revenue, USD Billion, 2021 - 2033)
-
Immunoassays
-
Hematology & Coagulation
-
Molecular Diagnostics
-
Microbiology
-
Clinical Chemistry
-
Histology/Cytology
-
Flow Cytometry
-
Mass Spectroscopy
-
Others
-
-
Application Outlook (Revenue, USD Billion, 2021 - 2033)
-
Oncology
-
Companion Diagnostics
-
Genomics Sequencing & Other
-
-
Genetic Disorders/Inherited Disease
-
Infectious & Parasitic Diseases
-
Immunology
-
Endocrine
-
Nutritional & Metabolic Disease
-
Cardiology
-
Mental/Behavioral Disorder
-
Pediatrics-specific Testing
-
Hematology/General Blood Testing
-
Bodily Fluid Analysis
-
Toxicology
-
Other Diseases
-
-
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
-
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
China
-
Japan
-
India
-
South Korea
-
Australia
-
Thailand
-
-
Latin America
-
Brazil
-
Mexico
-
Argentina
-
-
Middle East and Africa (MEA)
-
South Africa
-
Saudi Arabia
-
Kuwait
-
UAE
-
-
Research Methodology
The laboratory developed tests market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each laboratory developed tests segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Application
Revenue capture definition
Immunoassays
Revenue generated from laboratory-developed tests utilizing antigen-antibody interactions to detect, quantify, and monitor biomarkers associated with infectious diseases, autoimmune disorders, oncology, endocrinology, and therapeutic drug monitoring applications.
Hematology and Coagulation
Revenue captured from LDTs focused on blood cell analysis, clotting function assessment, bleeding disorders, thrombosis evaluation, leukemia diagnosis, and specialized hematological disease testing and monitoring.
Molecular Diagnostics
Revenue derived from LDTs employing PCR, NGS, sequencing, and other molecular techniques for detecting genetic mutations, infectious pathogens, cancer biomarkers, inherited disorders, and precision medicine applications.
Microbiology
Revenue generated from LDTs used to identify bacterial, viral, fungal, and parasitic organisms through culture-based methods, molecular testing, susceptibility testing, and infectious disease surveillance activities.
Clinical Chemistry
Revenue captured from LDTs measuring enzymes, proteins, metabolites, electrolytes, and other biochemical markers in blood and bodily fluids to support disease diagnosis and patient management.
Histology/Cytology
Revenue derived from LDTs involving microscopic examination of tissues and cells for cancer detection, disease characterization, pathology assessment, and monitoring treatment response across clinical settings.
Flow Cytometry
Revenue generated from LDTs utilizing flow cytometric analysis to evaluate cell populations, immune function, hematologic malignancies, transplantation compatibility, and biomarker expression for diagnostic purposes.
Mass Spectroscopy
Revenue captured from LDTs employing mass spectrometry technologies for highly sensitive identification and quantification of proteins, metabolites, drugs, hormones, and biomarkers across multiple disease areas.
Others
Revenue derived from laboratory-developed tests using specialized or emerging technologies not classified elsewhere, including advanced imaging-based diagnostics, proteomics, metabolomics, and novel analytical platforms.
Segment - Application
Revenue capture definition
Oncology
Revenue captured from laboratory-developed tests (LDTs) used for cancer diagnosis, biomarker identification, companion diagnostics, treatment selection, disease monitoring, recurrence detection, and precision oncology applications across solid tumors and hematological malignancies.
Genetic Disorders/Inherited Disease
Revenue generated from LDTs utilized for detecting inherited mutations, chromosomal abnormalities, rare genetic disorders, carrier screening, prenatal testing, and hereditary disease risk assessment to support clinical decision-making.
Infectious and Parasitic Diseases
Revenue derived from LDTs used for identifying bacterial, viral, fungal, and parasitic infections through molecular, serological, and microbiological testing to enable accurate diagnosis and treatment monitoring.
Immunology
Revenue generated from LDTs assessing immune system function, autoimmune diseases, immune deficiencies, inflammatory disorders, transplant compatibility, and immunotherapy-related biomarkers to support disease diagnosis and management.
Endocrine
Revenue captured from LDTs used for evaluating hormone levels, endocrine gland function, metabolic regulation disorders, and hormone-related diseases, including thyroid, adrenal, pituitary, and reproductive health conditions.
Nutritional and Metabolic Disease
Revenue derived from LDTs designed to detect nutritional deficiencies, metabolic abnormalities, enzyme disorders, inherited metabolic diseases, and biochemical imbalances affecting overall patient health and wellness.
Cardiology
Revenue generated from LDTs utilized for cardiovascular risk assessment, cardiac biomarker analysis, genetic cardiovascular testing, thrombosis evaluation, and monitoring heart-related diseases and treatment outcomes.
Mental/Behavioral Disorder
Revenue captured from LDTs supporting the diagnosis and management of psychiatric, neurological, and behavioral disorders through genetic, pharmacogenomic, biomarker, and neurochemical testing methodologies.
Pediatrics-Specific Testing
Revenue derived from LDTs developed specifically for pediatric populations, including newborn screening, developmental disorder assessment, congenital disease detection, and age-specific diagnostic testing applications.
Hematology/General Blood Testing
Revenue generated from LDTs used to evaluate blood cell disorders, coagulation abnormalities, anemia, leukemia, lymphomas, and other hematological conditions through specialized laboratory analysis.
Bodily Fluid Analysis
Revenue captured from LDTs performed on bodily fluids such as urine, cerebrospinal fluid, saliva, synovial fluid, and pleural fluid to diagnose and monitor various diseases.
Toxicology
Revenue derived from LDTs used for detecting drugs, toxins, chemicals, alcohol exposure, environmental contaminants, and substance abuse markers for clinical, forensic, and occupational health applications.
Other Diseases
Revenue generated from LDTs addressing disease areas not categorized elsewhere, including dermatological, respiratory, gastrointestinal, renal, ophthalmic, and emerging disease diagnostic applications.
Estimation Model
The Laboratory Developed Tests (LDTs) market was estimated using a combination of secondary research, primary interviews, and bottom-up forecasting methodologies. Revenue was calculated by analyzing test volumes, average reimbursement rates, and adoption levels across key application areas, including oncology, genetic disorders, infectious diseases, immunology, cardiology, and hematology. Market sizing incorporated revenues generated from laboratory-developed testing services, reagents, consumables, and assay-related activities. Regional estimates were developed based on disease prevalence, healthcare expenditure, laboratory infrastructure, and regulatory environments. Primary interviews with laboratory professionals, diagnostic experts, and industry participants were conducted to validate assumptions. Forecasts were generated using historical trends, technological advancements, precision medicine adoption, reimbursement dynamics, and future testing demand across major regions and end-user segments.
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
LDT Competitive Landscape & Technology Assessment – Molecular, Genomics & Specialty Diagnostics
Assessed global LDT ecosystem across clinical genomics, oncology, infectious disease, rare disease, and companion diagnostics. Evaluated key laboratory networks, hospital-based CLIA labs, NGS-based testing providers, and emerging precision diagnostics players.
Enabled benchmarking of leading lab providers and high-growth test segments, identified expansion opportunities in specialty and precision medicine testing, and assessed shift toward decentralized molecular diagnostics.
LDT Regulatory, Compliance & Reimbursement Landscape Assessment
Analyzed evolving regulatory framework including CLIA oversight, FDA proposed LDT regulations, and reimbursement pathways across CMS and private payers. Evaluated compliance readiness of major lab-developed test providers and impact on test commercialization.
Supported regulatory risk mapping, identified compliance gaps and readiness across lab operators, and highlighted implications of tightening oversight on innovation and market entry barriers.
LDT Innovation & Technology Assessment – NGS, PCR, Liquid Biopsy & AI-Enabled Diagnostics
Assessed adoption of next-generation sequencing (NGS), multiplex PCR, liquid biopsy, digital pathology, and AI-enabled diagnostic interpretation within LDT workflows. Evaluated automation, lab informatics integration, and turnaround time optimization trends.
Highlighted high-growth innovation segments, identified leaders in advanced molecular diagnostics, and assessed competitive positioning in precision, high-throughput, and AI-driven testing solutions.
Frequently Asked Questions About This Report
The laboratory developed tests market in Europe was identified as a lucrative region in this industry. Several initiatives are taken by various companies in Europe to develop and commercialize LDTs.
Based on technology, the molecular diagnostics segment led the market with the largest revenue share of 25.8% in 2025, attributed to the high adoption of molecular diagnostics tests for detection of all major parasitic, bacterial, and viral infections.
Based on application, the oncology segment led the market with the largest revenue share of 22.0% in 2025. This is attributable to the increasing prevalence of cancer which further propels the demand for IVD.
The laboratory developed tests market faces challenges stemming from evolving regulatory requirements and increasing scrutiny of test validation, quality management, and clinical performance standards. As LDTs become more widely used in critical healthcare decisions, laboratories are required to invest additional resources in documentation, validation studies, quality systems, and regulatory compliance processes.
Key factors that are driving the market growth include increasing demand for in vitro diagnostic tests that are currently unavailable in the market, increasing demand for the development of personalized medicine, and the fact that these tests do not require any regulatory approval. Moreover, these tests are available at lower cost and can aid in developing a wide range of diagnostic tools for various health conditions. Which further drives the growth of the market.
The global laboratory developed tests market size was valued at USD 14.1 billion in 2025 and is estimated at USD 15.1 billion for 2026.
The global laboratory developed tests market is expected to grow at a CAGR of 7.3% from 2026 to 2033, reaching USD 24.6 billion by 2033.
Some key players operating in the TDTs market include Quest Diagnostics Incorporated., 23andMe, Inc., Abbott, Guardant Health, NeoGenomics Laboratories., Siemens Healthineers AG, QIAGEN, Illumina, Inc., F. Hoffmann-La Roche Ltd.
North America dominated with a 37.5% revenue share in 2025.
About the Author(s)
Clinical Diagnostics Research Team
Healthcare · Clinical DiagnosticsThis report was authored by the clinical diagnostics research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the clinical diagnostics segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs — add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
